Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Clin Res Hepatol Gastroenterol ; 44(6): e141-e144, 2020 11.
Article in English | MEDLINE | ID: covidwho-592385

ABSTRACT

We present here the case of a 62-year-old man, who was referred to the emergency department with fever and cough for 3 days. He underwent liver transplantation 4 years earlier due to HCV and NASH-related cirrhosis with hepatocellular carcinoma. At admission he was in reduced general conditions. Nasopharyngeal smear specimen resulted positive for SARS-CoV-2 infection. Pulmonary low-dose CT-scan revealed bilateral subpleural ground-glass infiltrates. O2 saturation was 93%. A treatment with lopinavir/ritonavir and hydroxychloroquine twice daily was started. The patient received also cefepime and remained in isolation. Seven days later imaging showed a progression of the pulmonary infiltrates. Cefepime was replaced by meropenem. During the following 3 days the fever resolved, and the general conditions of the patient significantly improved. Consequently, treatment with lopinavir/ritonavir and hydroxychloroquine was stopped. The evolution of SARS-CoV-2 interstitial pneumonia in this immunosuppressed patient was moderate to severe and liver injury was not clinically significant. Despite its limitations, this case report confirm that the liver may be only mildly affected during SARS-CoV-2 infection, also in liver transplanted patients. Further studies are needed to assess whether the outcome of SARS-CoV-2 infection is worse in immunosuppressed patients than in the general population.


Subject(s)
COVID-19 Drug Treatment , Immunosuppression Therapy/adverse effects , Liver Transplantation , SARS-CoV-2 , Antiviral Agents/administration & dosage , COVID-19/epidemiology , COVID-19/pathology , Comorbidity , Humans , Hydroxychloroquine/administration & dosage , Liver Diseases/epidemiology , Liver Diseases/surgery , Lopinavir/administration & dosage , Lung/pathology , Male , Meropenem/administration & dosage , Middle Aged , Ritonavir/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL